Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Salix_Pharmaceuticals
gptkb:Bausch_+_Lomb |
| gptkbp:CEO |
gptkb:Joseph_C._Papa
2016-present |
| gptkbp:controversy |
price gouging
|
| gptkbp:focus |
cancer
cardiology endocrinology metabolic disorders neurology oncology rare diseases autoimmune diseases chronic diseases psychiatry dermatology cardiovascular diseases infectious diseases pain management women's health psychiatric disorders respiratory diseases ophthalmology gastrointestinal diseases urology gastroenterology neurological diseases men's health hormonal disorders dermatological diseases pain disorders |
| gptkbp:founded |
1960
|
| gptkbp:founder |
gptkb:M._S._(Mike)_McGowan
|
| gptkbp:headquarters |
gptkb:Laval,_Quebec,_Canada
gptkb:Laval,_Quebec |
| https://www.w3.org/2000/01/rdf-schema#label |
Valeant Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
$10 billion (2021)
|
| gptkbp:notable_event |
2016 restructuring plan
2015 stock price drop 2017 rebranding to Bausch Health |
| gptkbp:partnerships |
various healthcare organizations
|
| gptkbp:products |
generic pharmaceuticals
branded pharmaceuticals |
| gptkbp:research |
gptkb:Dr._Michael_Pearson
|
| gptkbp:revenue |
$8.4 billion (2015)
|
| gptkbp:stockExchange |
VRX
|
| gptkbp:subsidiary |
gptkb:Bausch_Health_Companies_Inc.
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.valeant.com
|